A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER] - PANTHER (version 6, 23 March 2012)

Phase 1

• Conditions: Metastatic Renal Cell Carcinoma

• Registration Number: EUCTR2009-016675-29-GB
• Lead Sponsor: Queen Mary university of London

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-03-17
• Study Completion: 2016-02-29
• Last Update Posted: 30 June 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 104

Inclusion Criteria

• Histopathologically confirmed clear cell carcinoma with measurable metastases on CT/MRI imaging (by RECIST). Only a component of clear cell is required.
• No prior systemic treatment or nephrectomy for RCC. Palliative radiotherapy is acceptable to non target lesions.
• Adequate organ function as defined by the following criteria:
i.Total serum bilirubin =1.5 x uln (patients with gilbert’s disease exempt)
ii.Serum transaminases (ALT) <3 x uln
iii.Calculated creatinine clearance >30ml/min
iv.Absolute neutrophil count (ANC) =1000/mm3 without growth factor support
v.Platelets = 75,000/mm3
• Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment.
• Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures
• ECOG performance status of 0, 1 or 2.
• 18 years or above (no upper age limit)
• Male or female
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

• Congestive heart failure (class III or IV NYHA), myocardial infarction or coronary artery bypass graft/ stenting or stroke in the previous six months, ongoing severe or unstable arrhythmia requiring medication.
• Previous treatment for renal cancer
• Pregnancy or breastfeeding. Female patients must be surgically sterile, be postmenopausal, or must agree to use adequate contraception during the period of therapy.
• Male patients must be surgically sterile or agree to use adequate contraception during the period of therapy.
• Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would in the judgement of the investigator, impart excess risk associated with study participation or study drug administration, or which, in the judgement of the investigator, would make the patient inappropriate for entry into this study
• Prolonged QT interval >480msecs
• Ongoing major gastrointestinal disease including ulcerative colitis, bleeding peptic ulcer disease or inflammatory bowel disease.
• Bleeding diathesis
• Current uncontrolled hypertension
• Another malignancy requiring treatment within the last 5 years. Local prostate cancer not requiring hormone therapy or an asymptomatic raised PSA is acceptable.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified